{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:45:34Z","timestamp":1793846734577,"version":"4.6.1"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurosci"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41583-019-0240-3","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T06:03:08Z","timestamp":1574920988000},"page":"21-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":547,"title":["Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-0106","authenticated-orcid":false,"given":"Rik","family":"van der Kant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S. B.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"240_CR1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol. Sci. 12, 383\u2013388 (1991).","journal-title":"Trends Pharmacol. Sci."},{"key":"240_CR2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe, D. J. The molecular pathology of Alzheimer\u2019s disease. Neuron 6, 487\u2013498 (1991).","journal-title":"Neuron"},{"key":"240_CR3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnen\/nlv028","volume":"75","author":"JM Ringman","year":"2016","unstructured":"Ringman, J. M. et al. Neuropathology of autosomal dominant Alzheimer disease in the National Alzheimer Coordinating Center Database. J. Neuropathol. Exp. Neurol. 75, 284\u2013290 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"240_CR4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awz019","volume":"142","author":"BA Gordon","year":"2019","unstructured":"Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer\u2019s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063\u20131076 (2019).","journal-title":"Brain"},{"key":"240_CR5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaneurol.2017.4907","volume":"75","author":"YT Quiroz","year":"2018","unstructured":"Quiroz, Y. T. et al. Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 75, 548\u2013556 (2018).","journal-title":"JAMA Neurol."},{"key":"240_CR6","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/brain\/awx171","volume":"140","author":"M Sch\u00f6ll","year":"2017","unstructured":"Sch\u00f6ll, M. et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer\u2019s disease. Brain 140, 2286\u20132294 (2017).","journal-title":"Brain"},{"key":"240_CR7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol. Med. 8, 595\u2013608 (2016).","journal-title":"EMBO Mol. Med."},{"key":"240_CR8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper, B. & Karran, E. The cellular phase of Alzheimer\u2019s disease. Cell 164, 603\u2013615 (2016).","journal-title":"Cell"},{"key":"240_CR9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N. Engl. J.\u00a0Med. 370, 322\u2013333 (2014).","journal-title":"N. Engl. J. Med."},{"key":"240_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki, S. et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res. Ther. 9, 95 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"240_CR11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s Disease. N. Engl. J. Med. 378, 321\u2013330 (2018).","journal-title":"N. Engl. J. Med."},{"key":"240_CR12","unstructured":"Roche. Roche to discontinue phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer\u2019s disease (AD) - other company programmes in AD continue. Roche https:\/\/www.roche.com\/media\/releases\/med-cor-2019-01-30.htm (2019)."},{"key":"240_CR13","unstructured":"Kemp, A. Update on phase III clinical trials of lanabecestat for Alzheimer\u2019s disease. AstraZeneca https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2018\/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html (2018)."},{"key":"240_CR14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMc1813435","volume":"380","author":"D Henley","year":"2019","unstructured":"Henley, D. et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer\u2019s disease. N. Engl. J. Med. 380, 1483\u20131485 (2019).","journal-title":"N. Engl. J. Med."},{"key":"240_CR15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan, M. F. et al. Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N. Engl. J. Med. 380, 1408\u20131420 (2019).","journal-title":"N. Engl. J. Med."},{"key":"240_CR16","unstructured":"Eisai. Eisai and Biogen to discontinue phase III clinical studies of BACE inhibitor elenbecestat in early Alzheimer\u2019s disease. Esai http:\/\/eisai.mediaroom.com\/2019-09-13-Eisai-And-Biogen-To-Discontinue-Phase-III-Clinical-Studies-Of-BACE-Inhibitor-Elenbecestat-In-Early-Alzheimers-Disease (2019)."},{"key":"240_CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza, F., Lozupone, M., Logroscino, G. & Imbimbo, B. P. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73\u201388 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"240_CR18","unstructured":"Biogen. Biogen and Eisai to discontinue phase 3 ENGAGE and EMERGE trials of aducanumab in Alzheimer\u2019s disease. Biogen http:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials (2019)."},{"key":"240_CR19","unstructured":"Biogen. Biogen plans regulatory filing for aducanumab in Alzheimer\u2019s disease based on new analysis of larger dataset from phase 3 studies. Biogen http:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease (2019)."},{"key":"240_CR20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nn.4018","volume":"18","author":"ES Musiek","year":"2015","unstructured":"Musiek, E. S. & Holtzman, D. M. Three dimensions of the amyloid hypothesis: time, space and \u2018wingmen\u2019. Nat. Neurosci. 18, 800\u2013806 (2015).","journal-title":"Nat. Neurosci."},{"key":"240_CR21","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1523\/JNEUROSCI.2177-05.2005","volume":"25","author":"RL Buckner","year":"2005","unstructured":"Buckner, R. L. et al. Molecular, structural, and functional characterization of Alzheimer\u2019s disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 25, 7709\u20137717 (2005).","journal-title":"J. Neurosci."},{"key":"240_CR22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe, M. J. et al. In vivo staging of regional amyloid deposition. Neurology 89, 2031\u20132038 (2017).","journal-title":"Neurology"},{"key":"240_CR23","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal, D. R., R\u00fcb, U., Orantes, M. & Braak, H. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791\u20131800 (2002).","journal-title":"Neurology"},{"key":"240_CR24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960\u2013969 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"240_CR25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"240_CR26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110\u2013119 (2016). This is one of the earliest cross-sectional tau PET studies to show that tau pathology increases with advancing age and AD progression, and corresponds to Braak staging of NFT pathology.","journal-title":"Ann. Neurol."},{"key":"240_CR27","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Sch\u00f6ll, M. et al. PET imaging of tau deposition in the\u00a0aging human brain. Neuron 89, 971\u2013982 (2016).","journal-title":"JAMA"},{"key":"240_CR28","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"240_CR29","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924\u20131938 (2015). This large meta-analysis provides prevalence estimates of A\u03b2 positivity in cognitively normal persons and patients with MCI.","journal-title":"JAMA"},{"key":"240_CR30","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack Jr.","year":"2013","unstructured":"Jack, C. R. Jr. & Holtzman, D. M. Biomarker modeling of Alzheimer\u2019s disease. Neuron 80, 1347\u20131358 (2013).","journal-title":"Neuron"},{"key":"240_CR31","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1093\/brain\/awv278","volume":"138","author":"A Altmann","year":"2015","unstructured":"Altmann, A. et al. Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain 138, 3734\u20133746 (2015).","journal-title":"Brain"},{"key":"240_CR32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016). This study shows that tau PET signal patterns, but not A\u03b2 PET signal patterns, correlate with sites of neurodegeneration and domain-specific cognitive impairment.","journal-title":"Brain"},{"key":"240_CR33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/brain\/awx320","volume":"141","author":"VJ Lowe","year":"2018","unstructured":"Lowe, V. J. et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer\u2019s dementia. Brain 141, 271\u2013287 (2018).","journal-title":"Brain"},{"key":"240_CR34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of 18F-flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"240_CR35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","volume":"139","author":"AJ Schwarz","year":"2016","unstructured":"Schwarz, A. J. et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139, 1539\u20131550 (2016). This study shows that tau PET can be used in vivo to replicate Braak staging of NFT pathology.","journal-title":"Brain"},{"key":"240_CR36","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele, R. et al. Associations between tau, A\u03b2, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601\u2013e612 (2019).","journal-title":"Neurology"},{"key":"240_CR37","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1212\/WNL.0000000000006075","volume":"91","author":"AJ Aschenbrenner","year":"2018","unstructured":"Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Morris, J. C. & Hassenstab, J. J. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91, e859\u2013e866 (2018).","journal-title":"Neurology"},{"key":"240_CR38","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin, A. et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain 140, 3286\u20133300 (2017).","journal-title":"Brain"},{"key":"240_CR39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.24910","volume":"81","author":"BJ Hanseeuw","year":"2017","unstructured":"Hanseeuw, B. J. et al. Fluorodeoxyglucose metabolism associated with tau\u2013amyloid interaction predicts memory decline. Ann. Neurol. 81, 583\u2013596 (2017).","journal-title":"Ann. Neurol."},{"key":"240_CR40","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.neuroimage.2017.05.049","volume":"157","author":"MR LaPoint","year":"2017","unstructured":"LaPoint, M. R. et al. The association between tau PET and retrospective cortical thinning in clinically normal elderly. Neuroimage 157, 612\u2013622 (2017).","journal-title":"Neuroimage"},{"key":"240_CR41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","volume":"16","author":"CR Jack","year":"2017","unstructured":"Jack, C. R. et al. Age-specific and sex-specific prevalence of cerebral \u03b2-amyloidosis, tauopathy, and\u00a0neurodegeneration in cognitively unimpaired individuals aged 50\u201395 years: a cross-sectional study. Lancet Neurol. 16, 435\u2013444 (2017).","journal-title":"Lancet Neurol."},{"key":"240_CR42","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1093\/brain\/awz268","volume":"142","author":"CR Jack","year":"2019","unstructured":"Jack, C. R. et al. The bivariate distribution of amyloid-\u03b2 and tau: relationship with established neurocognitive clinical syndromes. Brain 142, 3230\u20133242 (2019).","journal-title":"Brain"},{"key":"240_CR43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755\u2013766 (2014).","journal-title":"Acta Neuropathol."},{"key":"240_CR44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00401-015-1390-7","volume":"129","author":"C Duyckaerts","year":"2015","unstructured":"Duyckaerts, C. et al. PART is part of Alzheimer disease. Acta Neuropathol. 129, 749\u2013756 (2015).","journal-title":"Acta Neuropathol."},{"key":"240_CR45","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2967\/jnumed.118.221697","volume":"60","author":"H Cho","year":"2019","unstructured":"Braak, H. & Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351\u2013357 (1997).","journal-title":"J. Nucl. Med"},{"key":"240_CR46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price, J. L. & Morris, J. C. Tangles and plaques in nondemented aging and \u2018preclinical\u2019 Alzheimer\u2019s disease. Ann. Neurol. 45, 358\u2013368 (1999).","journal-title":"Ann. Neurol."},{"key":"240_CR47","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2967\/jnumed.118.221697","volume":"60","author":"H Cho","year":"2019","unstructured":"Cho, H. et al. Progressive tau accumulation in Alzheimer\u2019s disease: two-year follow-up study. J. Nucl. Med. 60, 1611\u20131621 (2019).","journal-title":"J. Nucl. Med."},{"key":"240_CR48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.25406","volume":"85","author":"TM Harrison","year":"2019","unstructured":"Harrison, T. M. et al. Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann. Neurol. 85, 229\u2013240 (2019).","journal-title":"Ann. Neurol."},{"key":"240_CR49","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain 141, 1517\u20131528 (2018). This pioneering longitudinal tau PET study shows progressive tau accumulation in A\u03b2-positive cognitively normal persons (0.5% annually) and individuals with clinical AD (3.0% annually).","journal-title":"Brain"},{"key":"240_CR50","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/brain\/awz090","volume":"142","author":"MJ Pontecorvo","year":"2019","unstructured":"Pontecorvo, M. J. et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia. Brain 142, 1723\u20131735 (2019).","journal-title":"Brain"},{"key":"240_CR51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.celrep.2014.12.034","volume":"10","author":"A Raj","year":"2015","unstructured":"Raj, A. et al. Network diffusion model of progression predicts longitudinal patterns of atrophy and metabolism in Alzheimer\u2019s disease. Cell Rep. 10, 359\u2013369 (2015).","journal-title":"Cell Rep."},{"key":"240_CR52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41593-018-0070-z","volume":"21","author":"HIL Jacobs","year":"2018","unstructured":"Jacobs, H. I. L. et al. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat. Neurosci. 21, 424\u2013431 (2018).","journal-title":"Nat. Neurosci."},{"key":"240_CR53","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neuron.2008.11.007","volume":"60","author":"SA Small","year":"2008","unstructured":"Small, S. A. & Duff, K. Linking A\u03b2 and tau in late-onset Alzheimer\u2019s disease: a dual pathway hypothesis. Neuron 60, 534\u2013542 (2008). This review presents the dual-cascade hypothesis of AD.","journal-title":"Neuron"},{"key":"240_CR54","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrn3012","volume":"12","author":"G Di Paolo","year":"2011","unstructured":"Di Paolo, G. & Kim, T.-W. Linking lipids to Alzheimer\u2019s disease: cholesterol and beyond. Nat. Rev. Neurosci. 12, 284\u2013296 (2011).","journal-title":"Nat. Rev. Neurosci."},{"key":"240_CR55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C-C Liu","year":"2013","unstructured":"Liu, C.-C., Liu, C.-C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106\u2013118 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"240_CR56","doi-asserted-by":"crossref","first-page":"968.e1","DOI":"10.1016\/j.cell.2013.10.037","volume":"155","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro, R., Br\u00e1s, J. & Hardy, J. SnapShot: genetics of Alzheimer\u2019s disease. Cell 155, 968.e1 (2013).","journal-title":"Cell"},{"key":"240_CR57","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","volume":"51","author":"IE Jansen","year":"2019","unstructured":"Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat. Genet. 51, 404\u2013413 (2019).","journal-title":"Nat. Genet."},{"key":"240_CR58","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat.\u00a0Genet. 51, 414\u2013430 (2019).","journal-title":"Nat. Genet."},{"key":"240_CR59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.neuron.2004.08.043","volume":"44","author":"B Hutter-Paier","year":"2004","unstructured":"Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C. & Sheng, M. TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91, 328\u2013340 (2016).","journal-title":"Neuron"},{"key":"240_CR60","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1074\/jbc.M111.274142","volume":"287","author":"RB Chan","year":"2012","unstructured":"Chan, R. B. et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J.\u00a0Biol. Chem. 287, 2678\u20132688 (2012).","journal-title":"J. Biol. Chem."},{"key":"240_CR61","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.neuron.2004.08.043","volume":"44","author":"B Hutter-Paier","year":"2004","unstructured":"Hutter-Paier, B. et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer\u2019s disease. Neuron 44, 227\u2013238 (2004). This study shows that cholesteryl esters can drive accumulation of A\u03b2 pathology in AD mice and that ACAT inhibitors have potential utility in the treatment of AD.","journal-title":"Neuron"},{"key":"240_CR62","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ncb1001-905","volume":"3","author":"L Puglielli","year":"2001","unstructured":"Puglielli, L. et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid \u03b2-peptide. Nat. Cell Biol. 3, 905\u2013912 (2001).","journal-title":"Nat. Cell Biol."},{"key":"240_CR63","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1073\/pnas.95.11.6460","volume":"95","author":"M Simons","year":"1998","unstructured":"Simons, M. et al. Cholesterol depletion inhibits the generation of \u03b2-amyloid in hippocampal neurons. Proc.\u00a0Natl Acad. Sci. USA 95, 6460\u20136464 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"240_CR64","doi-asserted-by":"crossref","first-page":"363.e9","DOI":"10.1016\/j.stem.2018.12.013","volume":"24","author":"R van der Kant","year":"2019","unstructured":"van der Kant, R. et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-\u03b2 in iPSC-derived Alzheimer\u2019s disease neurons. Cell Stem Cell 24, 363.e9\u2013375.e9 (2019). This study uses hiPSC-derived AD neurons to show that cholesteryl esters drive the accumulation of A\u03b2 and phosphorylated tau through correlated but independent mechanisms.","journal-title":"Cell Stem Cell"},{"key":"240_CR65","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1219988","volume":"336","author":"PJ Barrett","year":"2012","unstructured":"Barrett, P. J. et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168\u20131171 (2012).","journal-title":"Science"},{"key":"240_CR66","first-page":"3","volume":"165","author":"J Sepulcre","year":"2018","unstructured":"Shibuya, Y. et al. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer\u2019s disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol. Aging 36, 2248\u20132259 (2015).","journal-title":"Nat. Med."},{"key":"240_CR67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/NEN.0b013e31819ac3cb","volume":"68","author":"M Boimel","year":"2009","unstructured":"Boimel, M. et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J.\u00a0Neuropathol. Exp. Neurol. 68, 314\u2013325 (2009).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"240_CR68","first-page":"3","volume":"165","author":"J Sepulcre","year":"2018","unstructured":"Sepulcre, J. et al. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat. Med. 165, 3 (2018). This neurogenetic study shows that tau spread is associated with the expression of genes involved in axonal function, that A\u03b2 spread is associated with the expression of genes involved in dendritic function and that the spreading patterns of both tau and A\u03b2 are linked to the expression of genes involved in lipid metabolism.","journal-title":"Nat. Med."},{"key":"240_CR69","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.devcel.2015.01.022","volume":"32","author":"R van der Kant","year":"2015","unstructured":"van der Kant, R. & Goldstein, L. S. B. Cellular functions of the amyloid precursor protein from development to dementia. Dev. Cell 32, 502\u2013515 (2015).","journal-title":"Dev. Cell"},{"key":"240_CR70","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1073\/pnas.89.13.6075","volume":"89","author":"SS Sisodia","year":"1992","unstructured":"Sisodia, S. S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl Acad. Sci.\u00a0USA 89, 6075\u20136079 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"240_CR71","doi-asserted-by":"crossref","first-page":"E559","DOI":"10.1073\/pnas.1100745108","volume":"108","author":"R Sannerud","year":"2011","unstructured":"Sannerud, R. et al. ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1. Proc.\u00a0Natl Acad. Sci. USA 108, E559\u2013E568 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"240_CR72","doi-asserted-by":"crossref","first-page":"21279","DOI":"10.1074\/jbc.M111.338376","volume":"287","author":"Q Xiao","year":"2012","unstructured":"Xiao, Q. et al. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J. Biol. Chem. 287, 21279\u201321289 (2012).","journal-title":"J. Biol. Chem."},{"key":"240_CR73","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4386","volume":"5","author":"K Kanatsu","year":"2014","unstructured":"Kanatsu, K. et al. Decreased CALM expression reduces A\u03b242 to total A\u03b2 ratio through clathrin-mediated endocytosis of \u03b3-secretase. Nat. Commun. 5, 3386 (2014).","journal-title":"Nat. Commun."},{"key":"240_CR74","doi-asserted-by":"crossref","first-page":"102","DOI":"10.15252\/embr.201642738","volume":"18","author":"F Ubelmann","year":"2017","unstructured":"Ubelmann, F. et al. Bin1 and CD2AP polarise the endocytic generation of beta-amyloid. EMBO Rep. 18, 102\u2013122 (2017).","journal-title":"EMBO Rep."},{"key":"240_CR75","first-page":"2948","volume":"25","author":"T Miyagawa","year":"2016","unstructured":"Miyagawa, T. et al. BIN1 regulates BACE1 intracellular trafficking and amyloid-\u03b2 production. Hum. Mol. Genet. 25, 2948\u20132958 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"240_CR76","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nchembio.1508","volume":"10","author":"VJ Mecozzi","year":"2014","unstructured":"Andersen, O. M., Rudolph, I.-M. & Willnow, T. E. Risk factor SORL1: from genetic association to functional validation in Alzheimer\u2019s disease. Acta Neuropathol. 132, 653\u2013665 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"240_CR77","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ejhg.2017.87","volume":"25","author":"H Holstege","year":"2017","unstructured":"Holstege, H. et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer\u2019s disease: a clinical interpretation strategy. Eur. J. Hum. Genet. 25, 973\u2013981 (2017).","journal-title":"Eur. J. Hum. Genet."},{"key":"240_CR78","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nchembio.1508","volume":"10","author":"VJ Mecozzi","year":"2014","unstructured":"Mecozzi, V. J. et al. Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 10, 443\u2013449 (2014). This revolutionary biochemical study uses in silico screening to discover a small molecule that is capable of stabilizing the retromer complex.","journal-title":"Nat. Chem. Biol."},{"key":"240_CR79","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1523\/JNEUROSCI.4946-05.2006","volume":"26","author":"K Offe","year":"2006","unstructured":"Offe, K. et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J. Neurosci. 26, 1596\u20131603 (2006).","journal-title":"J. Neurosci."},{"key":"240_CR80","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1073\/pnas.0802545105","volume":"105","author":"A Muhammad","year":"2008","unstructured":"Muhammad, A. et al. Retromer deficiency observed in Alzheimer\u2019s disease causes hippocampal dysfunction, neurodegeneration, and A\u03b2 accumulation. Proc. Natl Acad. Sci. USA 105, 7327\u20137332 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"240_CR81","first-page":"5446","volume":"25","author":"M Sartori","year":"2019","unstructured":"Sartori, M. et al. BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with tau through Thr348 phosphorylation. Acta Neuropathol. 25, 5446\u20135422 (2019).","journal-title":"Acta Neuropathol."},{"key":"240_CR82","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fnmol.2018.00421","volume":"11","author":"A Lasorsa","year":"2018","unstructured":"Lasorsa, A. et al. Structural basis of tau interaction with BIN1 and regulation by tau phosphorylation. Front. Mol. Neurosci. 11, 421 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"240_CR83","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mp.2013.1","volume":"18","author":"J Chapuis","year":"2013","unstructured":"Chapuis, J. et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau\u00a0pathology. Mol. Psychiatry 18, 1225\u20131234 (2013). This study shows that BIN1 regulates tau-mediated neurotoxicity in different AD model systems and that BIN1 polymorphisms are correlated with tau pathology but not with A\u03b2 load in the AD brain.","journal-title":"Mol. Psychiatry"},{"key":"240_CR84","volume":"8","author":"EBC Glennon","year":"2013","unstructured":"Glennon, E. B. C. et al. BIN1 is decreased in sporadic but not familial Alzheimer\u2019s disease or in aging. PLOS\u00a0ONE 8, e78806 (2013).","journal-title":"PLOS ONE"},{"key":"240_CR85","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1074\/jbc.RA118.006379","volume":"294","author":"RJ Andrew","year":"2019","unstructured":"Andrew, R. J. et al. Reduction of the expression of the late-onset Alzheimer\u2019s disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model. J. Biol. Chem. 294, 4477\u20134487 (2019).","journal-title":"J. Biol. Chem."},{"key":"240_CR86","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09564-5","volume":"10","author":"N Franzmeier","year":"2019","unstructured":"Franzmeier, N., Rubinski, A., Neitzel, J. & Ewers, M., Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. Nat. Commun. 10, 1766 (2019).","journal-title":"Nat. Commun."},{"key":"240_CR87","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms5998","volume":"5","author":"K Moreau","year":"2014","unstructured":"Moreau, K. et al. PICALM modulates autophagy activity and tau accumulation. Nat. Commun. 5, 4998 (2014).","journal-title":"Nat. Commun."},{"key":"240_CR88","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.stemcr.2018.01.031","volume":"10","author":"JE Young","year":"2018","unstructured":"Young, J. E. et al. Stabilizing the retromer complex in a human stem cell model of Alzheimer\u2019s disease reduces tau phosphorylation independently of amyloid precursor protein. Stem Cell Rep. 10, 1046\u20131058 (2018). This study of hiPSC-derived AD neurons shows that retromer stabilization decreases A\u03b2 and p-tau levels through correlated but independent mechanisms.","journal-title":"Stem Cell Rep."},{"key":"240_CR89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cell.2014.12.019","volume":"160","author":"L Liu","year":"2015","unstructured":"Liu, L. et al. Glial Lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell 160, 177\u2013190 (2015).","journal-title":"Cell"},{"key":"240_CR90","first-page":"719.e6","volume":"26","author":"L Liu","year":"2017","unstructured":"Liu, L., MacKenzie, K. R., Putluri, N., Maleti\u0107-Savati\u0107, M. & Bellen, H. J. The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE\/D. Cell Metab. 26, 719.e6\u2013737.e6 (2017).","journal-title":"Cell Metab."},{"key":"240_CR91","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.294.5545.1354","volume":"294","author":"DH Mauch","year":"2001","unstructured":"Mauch, D. H. et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354\u20131357 (2001).","journal-title":"Science"},{"key":"240_CR92","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jalz.2018.02.009","volume":"14","author":"N Mattsson","year":"2018","unstructured":"Mattsson, N. et al. Prevalence of the apolipoprotein E \u03b54 allele in amyloid \u03b2 positive subjects across the spectrum of Alzheimer\u2019s disease. Alzheimers Dement. 14, 913\u2013924 (2018).","journal-title":"Alzheimers Dement."},{"key":"240_CR93","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"E Corder","year":"1993","unstructured":"Corder, E. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261, 921\u2013923 (1993).","journal-title":"Science"},{"key":"240_CR94","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.tins.2014.03.001","volume":"37","author":"DA Raichlen","year":"2014","unstructured":"Raichlen, D. A. & Alexander, G. E. Exercise, APOE genotype, and the evolution of the human lifespan. Trends Neurosci. 37, 247\u2013255 (2014).","journal-title":"Trends Neurosci."},{"key":"240_CR95","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1194\/jlr.R800069-JLR200","volume":"50","author":"RW Mahley","year":"2009","unstructured":"Mahley, R. W., Weisgraber, K. H. & Huang, Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer\u2019s disease to AIDS. J. Lipid Res. 50, S183\u2013S188 (2009).","journal-title":"J. Lipid Res."},{"key":"240_CR96","first-page":"427.e21","volume":"168","author":"Y-WA Huang","year":"2017","unstructured":"Huang, Y.-W. A., Zhou, B., Wernig, M. & S\u00fcdhof, T. C. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A\u03b2 secretion. Cell 168, 427.e21\u2013441.e21 (2017).","journal-title":"Cell"},{"key":"240_CR97","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1042\/BCJ20180068","volume":"475","author":"I Dafnis","year":"2018","unstructured":"Dafnis, I. et al. ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels\u00a0and A\u03b2 production independently of their cholesterol efflux capacity. Biochem. J. 475, 1839\u20131859 (2018).","journal-title":"Biochem. J."},{"key":"240_CR98","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Grothe, M. J. et al. Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology 88, 569\u2013576 (2017).","journal-title":"Nature"},{"key":"240_CR99","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","volume":"24","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. 24, 647\u2013657 (2018). This study uses hiPSC-derived neurons of different APOE genotypes to show that ApoE\u03b54 increases both A\u03b2 and p-tau through independent pathways, and that these effects can be rescued by treatment with small molecules that correct the structure of ApoE\u03b54.","journal-title":"Nat. Med."},{"key":"240_CR100","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523\u2013527 (2017). This elegant mouse study shows that the ApoE*4 genotype affects tau pathology in the absence of A\u03b2 pathology.","journal-title":"Nature"},{"key":"240_CR101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2015","unstructured":"Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 22\u201335 (2015).","journal-title":"Nat. Rev. Neurosci."},{"key":"240_CR102","first-page":"1141.e7","volume":"98","author":"Y-T Lin","year":"2018","unstructured":"Lin, Y.-T. et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1141.e7\u20131154.e7 (2018). This study characterizes gene-edited ApoE\u03b53 and ApoE\u03b54 hiPSC-derived neurons, astrocytes and microglia and demonstrates that the APOE*4 genotype suffices to render microglia more prone to inflammatory phenotypes.","journal-title":"Neuron"},{"key":"240_CR103","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fnins.2017.00702","volume":"11","author":"T Nuriel","year":"2017","unstructured":"Nuriel, T. et al. The endosomal\u2013lysosomal pathway is dysregulated by APOE4 expression in vivo. Front. Neurosci. 11, 702 (2017).","journal-title":"Front. Neurosci."},{"key":"240_CR104","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.7554\/eLife.40048","volume":"7","author":"X Xian","year":"2018","unstructured":"Xian, X. et al. Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer\u2019s disease. eLife 7, 7779 (2018).","journal-title":"eLife"},{"key":"240_CR105","first-page":"115.e5","volume":"96","author":"N Zhao","year":"2017","unstructured":"Zhao, N. et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron 96, 115.e5\u2013129.e5 (2017).","journal-title":"Neuron"},{"key":"240_CR106","doi-asserted-by":"crossref","first-page":"E6640","DOI":"10.1073\/pnas.1801612115","volume":"115","author":"H Prasad","year":"2018","unstructured":"Prasad, H. & Rao, R. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. Proc. Natl Acad. Sci. USA 115, E6640\u2013E6649 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"240_CR107","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1750-3639.1998.tb00166.x","volume":"8","author":"R Egensperger","year":"1998","unstructured":"Egensperger, R., K\u00f6sel, S., Eitzen, von, U. & Graeber,\u00a0M. B. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol. 8, 439\u2013447 (1998).","journal-title":"Brain Pathol."},{"key":"240_CR108","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.neurobiolaging.2007.11.014","volume":"30","author":"MP Vitek","year":"2009","unstructured":"Vitek, M. P., Brown, C. M. & Colton, C. A. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 30, 1350\u20131360 (2009).","journal-title":"Neurobiol. Aging"},{"key":"240_CR109","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3233\/JAD-180514","volume":"64","author":"EL Abner","year":"2018","unstructured":"Abner, E. L. et al. Diffuse amyloid-\u03b2 plaques, neurofibrillary tangles, and the impact of ApoE in elderly persons\u2019 brains lacking neuritic amyloid plaques. J. Alzheimers Dis. 64, 1307\u20131324 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"240_CR110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2018.07.215","volume":"15","author":"WR Bell","year":"2018","unstructured":"Bell, W. R. et al. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer\u2019s disease. Alzheimers Dement. 15, 8\u201316 (2018).","journal-title":"Alzheimers Dement."},{"key":"240_CR111","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/acn3.581","volume":"5","author":"CT McMillan","year":"2018","unstructured":"McMillan, C. T. et al. Alzheimer\u2019s genetic risk is reduced in primary age-related tauopathy: a potential model of resistance? Ann. Clin. Transl. Neurol. 5, 927\u2013934 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"240_CR112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13024-017-0184-x","volume":"12","author":"AG Efthymiou","year":"2017","unstructured":"Efthymiou, A. G. & Goate, A. M. Late onset Alzheimer\u2019s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 43 (2017).","journal-title":"Mol. Neurodegener."},{"key":"240_CR113","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00401-019-02026-8","volume":"138","author":"SJ van der Lee","year":"2019","unstructured":"van der Lee, S. J. et al. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer\u2019s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 138, 237\u2013250 (2019).","journal-title":"Acta Neuropathol."},{"key":"240_CR114","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-02926-5","volume":"9","author":"M Olah","year":"2018","unstructured":"Olah, M. et al. A transcriptomic atlas of aged human microglia. Nat. Commun. 9, 539 (2018).","journal-title":"Nat. Commun."},{"key":"240_CR115","doi-asserted-by":"crossref","first-page":"1276.e17","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169, 1276.e17\u20131290.e17 (2017).","journal-title":"Cell"},{"key":"240_CR116","doi-asserted-by":"crossref","first-page":"566.e9","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann, S. et al. The TREM2\u2013APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566.e9\u2013581.e9 (2017).","journal-title":"Immunity"},{"key":"240_CR117","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","volume":"217","author":"DV Hansen","year":"2018","unstructured":"Hansen, D. V., Hanson, J. E. & Sheng, M. Microglia in Alzheimer\u2019s disease. J. Cell Biol. 217, 459\u2013472 (2018).","journal-title":"J. Cell Biol."},{"key":"240_CR118","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nn.4132","volume":"18","author":"H Asai","year":"2015","unstructured":"Asai, H. et al. Depletion of microglia and inhibition of\u00a0exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584\u20131593 (2015).","journal-title":"Nat. Neurosci."},{"key":"240_CR119","volume":"5","author":"W Luo","year":"2015","unstructured":"Luo, W. et al. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep. 5, 11161 (2015).","journal-title":"Sci. Rep."},{"key":"240_CR120","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/brain\/awv081","volume":"138","author":"N Maphis","year":"2015","unstructured":"Maphis, N. et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain 138, 1738\u20131755 (2015).","journal-title":"Brain"},{"key":"240_CR121","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuron.2010.08.023","volume":"68","author":"K Bhaskar","year":"2010","unstructured":"Bhaskar, K. et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68, 19\u201331 (2010). This is one of the first studies to show that the activation of microglia (in the absence of A\u03b2) suffices to promote hyperphosphorylation of tau in neurons of tau-transgenic mice.","journal-title":"Neuron"},{"key":"240_CR122","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13024-017-0192-x","volume":"12","author":"CEG Leyns","year":"2017","unstructured":"Leyns, C. E. G. & Holtzman, D. M. Glial contributions to neurodegeneration in tauopathies. Mol. Neurodegener. 12, 50 (2017).","journal-title":"Mol. Neurodegener."},{"key":"240_CR123","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/374647a0","volume":"374","author":"L Meda","year":"1995","unstructured":"Meda, L. et al. Activation of microglial cells by \u03b2-amyloid protein and interferon-\u03b3. Nature 374, 647\u2013650 (1995).","journal-title":"Nature"},{"key":"240_CR124","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuropharm.2016.01.028","volume":"105","author":"T Jiang","year":"2016","unstructured":"Jiang, T. et al. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology 105, 196\u2013206 (2016).","journal-title":"Neuropharmacology"},{"key":"240_CR125","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1016\/j.neurobiolaging.2015.08.019","volume":"36","author":"T Jiang","year":"2015","unstructured":"Jiang, T. et al. Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiol. Aging 36, 3176\u20133186 (2015).","journal-title":"Neurobiol. Aging"},{"key":"240_CR126","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13024-017-0216-6","volume":"12","author":"SM Bemiller","year":"2017","unstructured":"Bemiller, S. M. et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol. Neurodegener. 12, 74 (2017).","journal-title":"Mol. Neurodegener."},{"key":"240_CR127","doi-asserted-by":"crossref","first-page":"11524","DOI":"10.1073\/pnas.1710311114","volume":"114","author":"CEG Leyns","year":"2017","unstructured":"Leyns, C. E. G. et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl Acad. Sci. USA 114, 11524\u201311529 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"240_CR128","first-page":"124ra29","volume":"4","author":"Y Shi","year":"2012","unstructured":"Moore, S. et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell\u00a0Rep. 11, 689\u2013696 (2015).","journal-title":"Sci. Transl Med."},{"key":"240_CR129","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1093\/hmg\/ddu064","volume":"23","author":"CR Muratore","year":"2014","unstructured":"Muratore, C. R. et al. The familial Alzheimer\u2019s disease APPV717I mutation alters APP processing and tau expression in iPSC-derived neurons. Hum. Mol. Genet. 23, 3523\u20133536 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"240_CR130","first-page":"124ra29","volume":"4","author":"Y Shi","year":"2012","unstructured":"Shi, Y. et al. A human stem cell model of early Alzheimer\u2019s disease pathology in Down syndrome. Sci.\u00a0Transl Med. 4, 124ra29 (2012).","journal-title":"Sci. Transl. Med."},{"key":"240_CR131","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10821","volume":"482","author":"MA Israel","year":"2012","unstructured":"Israel, M. A. et al. Probing sporadic and familial Alzheimer\u2019s disease using induced pluripotent stem cells. Nature 482, 216\u2013220 (2012).","journal-title":"Nature"},{"key":"240_CR132","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri, H. et al. APP mouse models for Alzheimer\u2019s disease preclinical studies. EMBO J. 36, 2473\u20132487 (2017).","journal-title":"EMBO J."},{"key":"240_CR133","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1523\/JNEUROSCI.23-17-06788.2003","volume":"23","author":"AM Cataldo","year":"2003","unstructured":"Cataldo, A. M. et al. App gene dosage modulates endosomal abnormalities of Alzheimer\u2019s disease in a segmental trisomy 16 mouse model of Down syndrome. J. Neurosci. 23, 6788\u20136792 (2003).","journal-title":"J. Neurosci."},{"key":"240_CR134","first-page":"3647.e2","volume":"25","author":"COY Hung","year":"2018","unstructured":"Hung, C. O. Y. & Livesey, F. J. Altered \u03b3-secretase processing of APP disrupts lysosome and autophagosome function in monogenic Alzheimer\u2019s disease. Cell Rep. 25, 3647.e2\u20133660.e2 (2018).","journal-title":"Cell Rep."},{"key":"240_CR135","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/mp.2015.97","volume":"21","author":"S Kim","year":"2016","unstructured":"Kim, S. et al. Evidence that the rab5 effector APPL1 mediates APP-\u03b2CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer\u2019s disease. Mol. Psychiatry 21, 707\u2013716 (2016).","journal-title":"Mol. Psychiatry"},{"key":"240_CR136","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.celrep.2016.09.034","volume":"17","author":"G Woodruff","year":"2016","unstructured":"Woodruff, G. et al. Defective transcytosis of APP and lipoproteins in human iPSC-derived neurons with familial Alzheimer\u2019s disease mutations. Cell Rep. 17, 759\u2013773 (2016).","journal-title":"Cell Rep."},{"key":"240_CR137","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuron.2019.07.010","volume":"104","author":"D Kwart","year":"2019","unstructured":"Kwart, D. et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP \u03b2-CTFs, not A\u03b2. Neuron 104, 256\u2013270 (2019).","journal-title":"Neuron"},{"key":"240_CR138","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/jnc.13632","volume":"139","author":"E Karran","year":"2016","unstructured":"Karran, E. & De Strooper, B. The amyloid cascade hypothesis: are we poised for success or failure? J.\u00a0Neurochem. 139, 237\u2013252 (2016).","journal-title":"J. Neurochem."},{"key":"240_CR139","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JAR Nicoll","year":"2006","unstructured":"Nicoll, J. A. R. et al. A\u03b2 species removal after A\u03b242 immunization. J. Neuropathol. Exp. Neurol. 65, 1040\u20131048 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"240_CR140","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","volume":"142","author":"JAR Nicoll","year":"2019","unstructured":"Nicoll, J. A. R. et al. Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease. Brain 142, 2113\u20132126 (2019).","journal-title":"Brain"},{"key":"240_CR141","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.15252\/emmm.201707809","volume":"9","author":"N Mattsson","year":"2017","unstructured":"Mattsson, N. et al. 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer\u2019s disease. EMBO Mol. Med. 9, 1212\u20131223 (2017).","journal-title":"EMBO Mol. Med."},{"key":"240_CR142","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/brain\/awm140","volume":"130","author":"K Buerger","year":"2007","unstructured":"Buerger, K. et al. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain 130, e82\u2013e82 (2007).","journal-title":"Brain"},{"key":"240_CR143","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jamaneurol.2018.3692","volume":"76","author":"R Smith","year":"2019","unstructured":"Smith, R., Wibom, M., Pawlik, D., Englund, E. & Hansson, O. Correlation of in vivo [18F]-flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 76, 310\u2013317 (2019). This study shows a strong correspondence between in vivo tau PET findings and postmortem tau pathology in a patient with familial AD.","journal-title":"JAMA Neurol."},{"key":"240_CR144","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.117.200006","volume":"59","author":"S Southekal","year":"2018","unstructured":"Southekal, S. et al. Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity. J. Nucl. Med. 59, 944\u2013951 (2018).","journal-title":"J. Nucl. Med."},{"key":"240_CR145","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.117.200691","volume":"59","author":"MD Devous","year":"2018","unstructured":"Devous, M. D. et al. Test-retest reproducibility for the tau PET imaging agent flortaucipir F18. J. Nucl. Med. 59, 937\u2013943 (2018).","journal-title":"J. Nucl. Med."},{"key":"240_CR146","doi-asserted-by":"crossref","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling, R. A. et al. The A4 study: stopping AD before\u00a0symptoms begin? Sci. Transl Med. 6, 228fs13 (2014).","journal-title":"Sci. Transl Med."},{"key":"240_CR147","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon, E. E. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 14, 399\u2013415 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"240_CR148","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","volume":"30","author":"Y Yamazaki","year":"2016","unstructured":"Yamazaki, Y., Painter, M. M., Bu, G. & Kanekiyo, T. Apolipoprotein E as a therapeutic target in Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs 30, 773\u2013789 (2016).","journal-title":"CNS Drugs"},{"key":"240_CR149","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1212\/WNL.0b013e318211c352","volume":"76","author":"VB Gupta","year":"2011","unstructured":"Gupta, V. B. et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76, 1091\u20131098 (2011).","journal-title":"Neurology"},{"key":"240_CR150","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","volume":"335","author":"PE Cramer","year":"2012","unstructured":"Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models. Science 335, 1503\u20131506 (2012).","journal-title":"Science"},{"key":"240_CR151","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1523\/JNEUROSCI.5198-13.2014","volume":"34","author":"A Boehm-Cagan","year":"2014","unstructured":"Boehm-Cagan, A. & Michaelson, D. M. Reversal of ApoE4-driven brain pathology and behavioral deficits by bexarotene. J. Neurosci. 34, 7293\u20137301 (2014).","journal-title":"J. Neurosci."},{"key":"240_CR152","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.1235505","volume":"340","author":"K Veeraraghavalu","year":"2013","unstructured":"Veeraraghavalu, K. et al. Comment on \u201cApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models\u201d. Science 340, 924\u2013992 (2013).","journal-title":"Science"},{"key":"240_CR153","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.1233937","volume":"340","author":"I Tesseur","year":"2013","unstructured":"Tesseur, I. et al. Comment on \u201cApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models\u201d. Science 340, 924\u2013992 (2013).","journal-title":"Science"},{"key":"240_CR154","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.1234089","volume":"340","author":"AR Price","year":"2013","unstructured":"Price, A. R. et al. Comment on \u201cApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models\u201d. Science 340, 924\u2013992 (2013).","journal-title":"Science"},{"key":"240_CR155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","volume":"8","author":"JL Cummings","year":"2016","unstructured":"Cummings, J. L. et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer\u2019s disease. Alzheimers Res. Ther. 8, 4 (2016).","journal-title":"Alzheimers Res. Ther."},{"key":"240_CR156","doi-asserted-by":"crossref","first-page":"18700","DOI":"10.1073\/pnas.0508693102","volume":"102","author":"S Ye","year":"2005","unstructured":"Ye, S. et al. Apolipoprotein (apo) E4 enhances amyloid \u03b2 peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl Acad. Sci. USA 102, 18700\u201318705 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"240_CR157","doi-asserted-by":"crossref","first-page":"17217","DOI":"10.1074\/jbc.M110.217380","volume":"286","author":"J Brodbeck","year":"2011","unstructured":"Brodbeck, J. et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem. 286, 17217\u201317226 (2011).","journal-title":"J. Biol. Chem."},{"key":"240_CR158","unstructured":"E\u00b7Scape Bio. ApoE4 is the strongest genetic risk factor for late-onset Alzheimer\u2019s disease. Individuals carry one of three variants of the ApoE gene: ApoE2, ApoE3, or ApoE4. E\u22c5Scape Bio http:\/\/www.e-scapebio.com\/science\/index.php (2019)."},{"key":"240_CR159","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tins.2013.11.006","volume":"37","author":"J Neefjes","year":"2014","unstructured":"Neefjes, J. & van der Kant, R. Stuck in traffic: an emerging theme in diseases of the nervous system. Trends Neurosci. 37, 66\u201376 (2014).","journal-title":"Trends Neurosci."},{"key":"240_CR160","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ana.20667","volume":"58","author":"SA Small","year":"2005","unstructured":"Small, S. A. et al. Model-guided microarray implicates the retromer complex in Alzheimer\u2019s disease. Ann. Neurol. 58, 909\u2013919 (2005).","journal-title":"Ann. Neurol."},{"issue":"7, Suppl.","key":"240_CR161","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.jalz.2019.09.058","volume":"15","author":"YH Qureshi","year":"2019","unstructured":"Qureshi, Y. H. et al. Retromer repletion with AAV9\u2013VPS35 restores endosomal function in the mouse hippocampus. Alzheimers Dement. 15, 1597\u20131598 (2019).","journal-title":"Alzheimers Dement."},{"key":"240_CR162","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358\u2013378 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"240_CR163","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri.2017.125","volume":"18","author":"Q Li","year":"2018","unstructured":"Li, Q. & Barres, B. A. Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 18, 225\u2013242 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"240_CR164","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2353\/ajpath.2010.100265","volume":"177","author":"S Lee","year":"2010","unstructured":"Lee, S. et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer\u2019s disease mouse models. Am. J. Pathol. 177, 2549\u20132562 (2010).","journal-title":"Am. J. Pathol."},{"key":"240_CR165","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1523\/JNEUROSCI.4403-10.2010","volume":"30","author":"Z Liu","year":"2010","unstructured":"Liu, Z., Condello, C., Schain, A., Harb, R. & Grutzendler, J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-\u03b2 phagocytosis. J. Neurosci. 30, 17091\u201317101 (2010).","journal-title":"J. Neurosci."},{"key":"240_CR166","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13024-018-0280-6","volume":"13","author":"X Xiang","year":"2018","unstructured":"Xiang, X. et al. The Trem2 R47H Alzheimer\u2019s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans. Mol. Neurodegener. 13, 49 (2018).","journal-title":"Mol. Neurodegener."},{"key":"240_CR167","first-page":"273","volume":"4","author":"J Alam","year":"2017","unstructured":"Alam, J., Blackburn, K. & Patrick, D. Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of\u00a0p38\u03b1 to reverse synaptic dysfunction in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 4, 273\u2013278 (2017).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"240_CR168","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acn3.549","volume":"5","author":"P Scheltens","year":"2018","unstructured":"Scheltens, P. et al. An exploratory clinical study of p38\u03b1 kinase inhibition in Alzheimer\u2019s disease. Ann.\u00a0Clin. Transl. Neurol. 5, 464\u2013473 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"240_CR169","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-8-79","volume":"8","author":"AD Bachstetter","year":"2011","unstructured":"Bachstetter, A. D. et al. Microglial p38\u03b1 MAPK is a key regulator of proinflammatory cytokine up-regulation induced by Toll-like receptor (TLR) ligands or beta-amyloid (A\u03b2). J. Neuroinflammation 8, 79 (2011).","journal-title":"J. Neuroinflammation"},{"key":"240_CR170","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/ng.3916","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer\u2019s disease. Nat. Genet. 49, 1373\u20131384 (2017).","journal-title":"Nat. Genet."},{"key":"240_CR171","doi-asserted-by":"crossref","first-page":"22091","DOI":"10.1074\/jbc.M110.102277","volume":"285","author":"M Shinohara","year":"2010","unstructured":"Shinohara, M. et al. Reduction of brain beta-amyloid (A\u03b2) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of\u00a0amyloid precursor protein C-terminal fragments (APP-CTFs) and A\u03b2 clearance. J. Biol. Chem. 285, 22091\u201322102 (2010).","journal-title":"J. Biol. Chem."},{"key":"240_CR172","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.brainres.2010.11.067","volume":"1371","author":"T Kurata","year":"2011","unstructured":"Kurata, T. et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 1371, 161\u2013170 (2011).","journal-title":"Brain Res."},{"key":"240_CR173","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaneurol.2016.3783","volume":"74","author":"JM Zissimopoulos","year":"2017","unstructured":"Zissimopoulos, J. M., Barthold, D., Brinton, R. D. &\u00a0Joyce, G. Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol. 74, 225\u2013232 (2017).","journal-title":"JAMA Neurol."},{"key":"240_CR174","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/archneurol.2011.203","volume":"68","author":"NE Shepardson","year":"2011","unstructured":"Shepardson, N. E., Shankar, G. M. & Selkoe, D. J. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 68, 1239\u20131244 (2011).","journal-title":"Arch. Neurol."},{"key":"240_CR175","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneurol.2011.242","volume":"68","author":"NE Shepardson","year":"2011","unstructured":"Shepardson, N. E., Shankar, G. M. & Selkoe, D. J. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch.\u00a0Neurol. 68, 1385\u20131392 (2011).","journal-title":"Arch. Neurol."},{"key":"240_CR176","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00842920 (2019)."},{"key":"240_CR177","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12031-007-0040-5","volume":"33","author":"GL Vega","year":"2007","unstructured":"Vega, G. L. & Weiner, M. F. Plasma 24S hydroxycholesterol response to statins in Alzheimer\u2019s disease patients: effects of gender, CYP46, and ApoE polymorphisms. J. Mol. Neurosci. 33, 51\u201355 (2007).","journal-title":"J. Mol. Neurosci."},{"key":"240_CR178","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WAD.0b013e3181d61fea","volume":"24","author":"A Serrano-Pozo","year":"2010","unstructured":"Serrano-Pozo, A. et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis. Assoc. Disord. 24, 220\u2013226 (2010).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"240_CR179","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1212\/WNL.0000000000004392","volume":"89","author":"G Li","year":"2017","unstructured":"Li, G. et al. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults. Neurology 89, 1251\u20131255 (2017).","journal-title":"Neurology"},{"key":"240_CR180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/JAD-2006-10408","volume":"10","author":"RG Riekse","year":"2006","unstructured":"Riekse, R. G. et al. Effect of statins on Alzheimer\u2019s disease biomarkers in cerebrospinal fluid. J. Alzheimers Dis. 10, 399\u2013406 (2006).","journal-title":"J. Alzheimers Dis."},{"key":"240_CR181","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1074\/jbc.M113.532846","volume":"289","author":"N Mast","year":"2014","unstructured":"Mast, N. et al. Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice. J. Biol. Chem. 289, 3529\u20133538 (2014).","journal-title":"J. Biol. Chem."},{"key":"240_CR182","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.neuropharm.2017.06.026","volume":"123","author":"N Mast","year":"2017","unstructured":"Mast, N. et al. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer\u2019s disease. Neuropharmacology 123, 465\u2013476 (2017). This study first identifies small molecules (including efavirenz) that act as allosteric activators of CYP46A1 and specifically regulate neuronal cholesterol metabolism.","journal-title":"Neuropharmacology"},{"key":"240_CR183","doi-asserted-by":"crossref","first-page":"12934","DOI":"10.1074\/jbc.M117.794909","volume":"292","author":"N Mast","year":"2017","unstructured":"Mast, N. et al. In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds. J.\u00a0Biol. Chem. 292, 12934\u201312946 (2017).","journal-title":"J. Biol. Chem."},{"key":"240_CR184","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1074\/jbc.M116.723577","volume":"291","author":"KW Anderson","year":"2016","unstructured":"Anderson, K. W. et al. Mapping of the allosteric site in cholesterol hydroxylase CYP46A1 for efavirenz, a drug that stimulates enzyme activity. J. Biol. Chem. 291, 11876\u201311886 (2016).","journal-title":"J. Biol. Chem."},{"key":"240_CR185","first-page":"1","volume":"15","author":"AM Petrov","year":"2019","unstructured":"Petrov, A. M. et al. CYP46A1 activation by Efavirenz leads to behavioral improvement without significant changes in amyloid plaque load in the brain of 5XFAD mice. Neurotherapeutics 15, 1\u201315 (2019).","journal-title":"Neurotherapeutics"},{"key":"240_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03706885 (2019)."},{"key":"240_CR187","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K Santacruz","year":"2010","unstructured":"Hudry, E. et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer\u2019s disease. Mol. Ther. 18, 44\u201353 (2010).","journal-title":"Science"},{"key":"240_CR188","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000113705","volume":"5","author":"HJ Huttunen","year":"2008","unstructured":"Huttunen, H. J. & Kovacs, D. M. ACAT as a drug target for Alzheimer\u2019s disease. Neurodegener. Dis. 5, 212\u2013214 (2008).","journal-title":"Neurodegener. Dis."},{"key":"240_CR189","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K Santacruz","year":"2005","unstructured":"Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476\u2013481 (2005). This is the first study to show that reducing tau expression in tau transgenic mice can rescue neuronal loss and behavioural deficits, even when extensive neurofibrillary tangles are already present.","journal-title":"Science"},{"key":"240_CR190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41593-018-0289-8","volume":"22","author":"MA Busche","year":"2019","unstructured":"Busche, M. A. et al. Tau impairs neural circuits, dominating amyloid-\u03b2 effects, in Alzheimer models in vivo. Nat. Neurosci. 22, 57\u201364 (2019).","journal-title":"Nat. Neurosci."},{"key":"240_CR191","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl Med. 9, eaag0481 (2017).","journal-title":"Sci. Transl. Med."},{"key":"240_CR192","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1093\/brain\/awy117","volume":"141","author":"SL DeVos","year":"2018","unstructured":"DeVos, S. L. et al. Tau reduction in the presence of amyloid-\u03b2 prevents tau pathology and neuronal death in vivo. Brain 141, 2194\u20132212 (2018).","journal-title":"Brain"},{"key":"240_CR193","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","volume":"293","author":"J Lewis","year":"2001","unstructured":"Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487\u20131491 (2001).","journal-title":"Science"},{"key":"240_CR194","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo, S. et al. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular A\u03b2 and synaptic dysfunction. Neuron 39, 409\u2013421 (2003).","journal-title":"Neuron"},{"key":"240_CR195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00401-016-1577-6","volume":"132","author":"I Lauritzen","year":"2016","unstructured":"Lauritzen, I. et al. Intraneuronal aggregation of the \u03b2-CTF fragment of APP (C99) induces A\u03b2-independent lysosomal-autophagic pathology. Acta Neuropathol. 132, 257\u2013276 (2016).","journal-title":"Acta Neuropathol."},{"key":"240_CR196","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06813-x","volume":"9","author":"G Barthet","year":"2018","unstructured":"Barthet, G. et al. Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity. Nat. Commun. 9, 4780 (2018).","journal-title":"Nat. Commun."},{"key":"240_CR197","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fncel.2018.00121","volume":"12","author":"S Mondrag\u00f3n-Rodr\u00edguez","year":"2018","unstructured":"Mondrag\u00f3n-Rodr\u00edguez, S., Gu, N., Manseau, F. & Williams, S. Alzheimer\u2019s transgenic model is characterized by very early brain network alterations and \u03b2-CTF fragment accumulation: reversal by \u03b2-secretase inhibition. Front. Cell. Neurosci. 12, 121 (2018).","journal-title":"Front. Cell. Neurosci."},{"key":"240_CR198","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-1326-8-15","volume":"8","author":"J Kim","year":"2013","unstructured":"Kim, J. et al. Normal cognition in transgenic BRI2\u2013A\u03b2 mice. Mol. Neurodegener. 8, 15 (2013).","journal-title":"Mol. Neurodegener."},{"key":"240_CR199","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.1062097","volume":"293","author":"J G\u00f6tz","year":"2001","unstructured":"G\u00f6tz, J., Chen, F., van Dorpe, J. & Nitsch, R. M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by A\u03b2 42 fibrils. Science 293, 1491\u20131495 (2001).","journal-title":"Science"},{"key":"240_CR200","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.2353\/ajpath.2007.070403","volume":"171","author":"T Bolmont","year":"2007","unstructured":"Bolmont, T. et al. Induction of tau pathology by intracerebral infusion of amyloid-\u03b2-containing brain extract and by amyloid-\u03b2deposition in APP\u00d7tau transgenic mice. Am. J. Pathol. 171, 2012\u20132020 (2007).","journal-title":"Am. J. Pathol."},{"key":"240_CR201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","volume":"43","author":"S Oddo","year":"2004","unstructured":"Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. A\u03b2 immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321\u2013332 (2004).","journal-title":"Neuron"},{"key":"240_CR202","doi-asserted-by":"crossref","first-page":"39413","DOI":"10.1074\/jbc.M608485200","volume":"281","author":"S Oddo","year":"2006","unstructured":"Oddo, S. et al. Reduction of soluble A\u03b2 and tau, but not soluble A\u03b2 alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281, 39413\u201339423 (2006).","journal-title":"J. Biol. Chem."},{"key":"240_CR203","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat.\u00a0Rev. Drug Discov. 10, 698\u2013712 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"240_CR204","doi-asserted-by":"crossref","first-page":"11341","DOI":"10.1074\/jbc.RA117.000441","volume":"293","author":"LK Fong","year":"2018","unstructured":"Fong, L. K. et al. Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-\u03b2 clearance in human astrocytes. J. Biol. Chem. 293, 11341\u201311357 (2018).","journal-title":"J. Biol. Chem."},{"key":"240_CR205","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.celrep.2018.07.094","volume":"24","author":"P Garcia-Reitboeck","year":"2018","unstructured":"Garcia-Reitboeck, P. et al. Human induced pluripotent stem cell-derived microglia-like cells harboring TREM2 missense mutations show specific deficits in phagocytosis. Cell Rep. 24, 2300\u20132311 (2018).","journal-title":"Cell Rep."},{"key":"240_CR206","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.stem.2015.02.004","volume":"16","author":"JE Young","year":"2015","unstructured":"Young, J. E. et al. Elucidating molecular phenotypes caused by the SORL1 Alzheimer\u2019s disease genetic risk factor using human induced pluripotent stem cells. Cell\u00a0Stem Cell 16, 373\u2013385 (2015).","journal-title":"Cell Stem Cell"},{"key":"240_CR207","doi-asserted-by":"crossref","first-page":"1112.e9","DOI":"10.1016\/j.celrep.2019.01.023","volume":"26","author":"K Meyer","year":"2019","unstructured":"Meyer, K. et al. REST and neural gene network dysregulation in iPSC models of Alzheimer\u2019s disease. Cell Rep. 26, 1112.e9\u20131127.e9 (2019).","journal-title":"Cell Rep."},{"key":"240_CR208","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.celrep.2017.10.109","volume":"21","author":"T Kondo","year":"2017","unstructured":"Kondo, T. et al. iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid \u03b2 combination for Alzheimer\u2019s disease. Cell Rep. 21, 2304\u20132312 (2017).","journal-title":"Cell Rep."},{"key":"240_CR209","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.stemcr.2017.02.006","volume":"8","author":"PW Brownjohn","year":"2017","unstructured":"Brownjohn, P. W. et al. Phenotypic screening identifies modulators of amyloid precursor protein processing in human stem cell models of Alzheimer\u2019s disease. Stem Cell Rep. 8, 870\u2013882 (2017).","journal-title":"Stem Cell Rep."},{"key":"240_CR210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.stem.2013.01.009","volume":"12","author":"T Kondo","year":"2013","unstructured":"Kondo, T. et al. Modeling Alzheimer\u2019s disease with iPSCs reveals stress phenotypes associated with intracellular A\u03b2 and differential drug responsiveness. Cell Stem Cell 12, 487\u2013496 (2013).","journal-title":"Cell Stem Cell"},{"key":"240_CR211","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nmeth.4291","volume":"14","author":"N Yang","year":"2017","unstructured":"Yang, N. et al. Generation of pure GABAergic neurons by transcription factor programming. Nat. Methods 14, 621\u2013628 (2017).","journal-title":"Nat. Methods"},{"key":"240_CR212","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","volume":"78","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785\u2013798 (2013).","journal-title":"Neuron"},{"key":"240_CR213","doi-asserted-by":"crossref","first-page":"2199.e6","DOI":"10.1016\/j.celrep.2019.04.058","volume":"27","author":"M Meijer","year":"2019","unstructured":"Meijer, M. et al. A single-cell model for synaptic transmission and plasticity in human iPSC-derived neurons. Cell Rep. 27, 2199.e6\u20132211.e6 (2019).","journal-title":"Cell Rep."},{"key":"240_CR214","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nature13800","volume":"515","author":"SH Choi","year":"2014","unstructured":"Choi, S. H. et al. A three-dimensional human neural cell culture model of Alzheimer\u2019s disease. Nature 515, 274\u2013278 (2014).","journal-title":"Nature"},{"key":"240_CR215","doi-asserted-by":"crossref","first-page":"1066.e8","DOI":"10.1016\/j.neuron.2017.02.001","volume":"93","author":"I Espuny-Camacho","year":"2017","unstructured":"Espuny-Camacho, I. et al. Hallmarks of Alzheimer\u2019s disease in stem-cell-derived human neurons transplanted into mouse brain. Neuron 93, 1066.e8\u20131081.e8 (2017).","journal-title":"Neuron"},{"key":"240_CR216","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1096\/fj.09-134999","volume":"23","author":"HJ Huttunen","year":"2009","unstructured":"Huttunen, H. J. et al. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J. 23, 3819\u20133828 (2009).","journal-title":"FASEB J."}],"container-title":["Nature Reviews Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41583-019-0240-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41583-019-0240-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41583-019-0240-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:15:29Z","timestamp":1684606529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41583-019-0240-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":216,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1038\/s41583-019-0240-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736992997.793589772","asserted-by":"object"}]},"ISSN":["1471-003X","1471-0048"],"issn-type":[{"value":"1471-003X","type":"print"},{"value":"1471-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"21 October 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}